Q3 Earnings Estimate for AnaptysBio Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright lifted their Q3 2026 earnings estimates for AnaptysBio in a research report issued to clients and investors on Tuesday, September 22nd. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn $0.00 per share for the quarter, up from their previous estimate of ($0.03). HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for AnaptysBio’s FY2026 earnings at ($1.30) EPS, FY2027 earnings at $2.42 EPS, FY2028 earnings at $4.57 EPS, FY2029 earnings at $5.23 EPS and FY2030 earnings at $6.50 EPS.

Several other analysts also recently commented on ANAB. Cantor Fitzgerald reiterated an “overweight” rating on shares of AnaptysBio in a report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. TD Cowen decreased their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Wolfe Research reiterated an “outperform” rating and issued a $78.00 price objective on shares of AnaptysBio in a research note on Monday, August 31st. Finally, Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research report on Tuesday, August 25th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and an average target price of $79.15.

AnaptysBio Stock Down 5.8%

Shares of NASDAQ:ANAB opened at $50.77 on Thursday. The business’s 50 day moving average is $55.57 and its 200 day moving average is $59.17. AnaptysBio has a 12-month low of $13.86 and a 12-month high of $72.36. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 9.45 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57. The firm had revenue of $27.49 million during the quarter, compared to analysts’ expectations of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same period last year, the company earned ($1.30) earnings per share.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in AnaptysBio in the second quarter valued at about $124,473,000. Affinity Asset Advisors LLC raised its holdings in shares of AnaptysBio by 111.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after purchasing an additional 495,308 shares during the period. 683 Capital Management LLC lifted its position in shares of AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 101,093 shares during the last quarter. Palo Alto Investors LP purchased a new stake in AnaptysBio during the second quarter valued at about $40,735,508. Finally, First Light Asset Management LLC lifted its stake in shares of AnaptysBio by 2.9% during the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock valued at $39,285,000 after buying an additional 16,573 shares in the last quarter.

Key Stories Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $95 price target, while raising its Q3 2026 EPS forecast to $0.00 from a projected loss of $0.03 and improving its FY2026 estimate to a loss of $1.30 per share from a loss of $2.60. The firm still expects AnaptysBio to become profitable beginning in FY2027.
• Positive Sentiment: AnaptysBio’s latest quarterly results substantially exceeded expectations, with $5.11 in EPS versus the consensus estimate of a $0.46 loss and revenue of $27.49 million versus expectations of $14.06 million. However, the profit was helped by a substantial $181.5 million tax benefit, which may limit the recurring significance of the earnings beat. AnaptysBio Swings To Profit in Q2 Reflecting $181.5 Million Tax Benefit
• Positive Sentiment: Leerink Partners continues to rate the stock Outperform and its revised $81 price target implies significant upside from the referenced $50.77 level, although the target was reduced from $90. AnaptysBio analyst information
• Neutral Sentiment: Analyst coverage remains broadly constructive: AnaptysBio has received an average “Moderate Buy” recommendation, with analysts focusing on the company’s potential transition to sustained profitability.
• Negative Sentiment: HC Wainwright cut its longer-term EPS forecasts for FY2027 through FY2030: FY2027 to $2.42 from $2.86, FY2028 to $4.57 from $5.42, FY2029 to $5.23 from $6.20, and FY2030 to $6.50 from $7.64. These reductions suggest a more cautious view of AnaptysBio’s eventual earnings power despite the unchanged Buy rating and $95 target.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.